insitro, the AI therapeutics company built on causal biology, announces the acquisition of CombinAbleAI and the launch of insitro’s TherML™ (Therapeutic Machine Learning) platform. The acquisition, which is expected to close in late January 2026, will complete insitro’s full stack, modality-agnostic capability spanning small molecules, oligonucleotides, antibodies, and other complex biologics with precision – enabling biology to guide both modality selection and molecular design from target discovery through developability assessment. This integrated approach accelerates the generation of clinic-ready assets while reducing late-stage development risk.
Read the full article: insitro to Acquire CombinAbleAI to Complete Its Full Stack, Modality-Agnostic AI Platform for Drug Discovery and Design //
Source: https://www.businesswire.com/news/home/20260112368387/en/insitro-to-Acquire-CombinAbleAI-to-Complete-its-Full-Stack-Modality-Agnostic-AI-Platform-for-Drug-Discovery-and-Design